Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Gastrointestinal Cancer
  •  Hematology
  •  Paediatric Cancers
  •  Chemoprevention
  •  Ovarian Cancer
  •  Radiation Oncology
  •  Radiological Techniques and Scans
  •  Sarcomas

Abstract

Citation: Clin Oncol. 2022;7(1):1900.DOI: 10.25107/2474-1663.1900

Synchronous Pancreatic Neuroendocrine Tumor and Pancreatic Cyst: A Case Report

Hao Hua, Xun Ran, Yi-Gang Chen, Chao-Quan Hu, Fu-Tang Li, Shi Zuo, Cheng-Yi Sun and Chao Yu*

Department of Hepatic-Biliary-Pancreatic Surgery, The Affiliate Hospital of Guizhou Medical University, China

*Correspondance to: Chao Yu 

 PDF  Full Text Case Report | Open Access

Abstract:

Synchronous pancreatic Neuroendocrine Tumor (pNET) and pancreatic cyst are very rare. Herein, we report a case of pNET combined with a pancreatic cyst in a 49-year-old female. The patient first presented with a complaint of persistent pain in the right upper abdomen. As a follow-up, CT scan was performed that showed a solid pNET of 2-cm in diameter and a pancreatic cyst of 5-cm in the tail. Then, the subsequent distal pancreatectomy with splenectomy was performed. The tumor histologically diagnosed with a cystic pancreatic neuroendocrine tumor. Therefore, it is critical to get a deep insight into this seldom tumor. Surgery remains the standard option of treatment for pNET.

Keywords:

Pancreatic cyst; Pancreatic neuroendocrine tumor; Splenectomy

Cite the Article:

Hua H, Ran X, Chen Y-G, Hu C-Q, Li F-T, Zuo S, et al. Synchronous Pancreatic Neuroendocrine Tumor and Pancreatic Cyst: A Case Report. Clin Oncol. 2022;7:1900..

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Erlotinib Treatment Beyond Progression in EGFR Mutant Patients Who Have Responded to EGFR TKIs in Stage IIIB/IV NSCLC: An Open Label Randomized Trial
 Abstract  PDF  Full Text
Application of First-Line Steady-State Mobilization vs. Conventional Chemotherapy Mobilization for Peripheral Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma Patients
 Abstract  PDF  Full Text
View More...